Skip to main content
. 2020 Jun 16;9(6):1469. doi: 10.3390/cells9061469

Figure 3.

Figure 3

Harmol is a competitive antagonist of the full-length AR. Dose response curves performed with harmol, harmine, ellipticine and the AR antagonist enzalutamide antagonist activity in U2OS-hAR-ARE-Luc cells (A) and U2OS-ARE-Luc control cells (B). Cells were incubated for 16 h with 0, 0.03, 0.1, 0.3, 1, and 3 µM of tested compounds in the absence (□) or in the presence of R1881 1 nM (○) and100 nM (●) R1881.